BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24182742)

  • 1. The diurnal and nocturnal effect of travoprost with sofZia on intraocular pressure and ocular perfusion pressure.
    Seibold LK; Kahook MY
    Am J Ophthalmol; 2014 Jan; 157(1):44-49.e1. PubMed ID: 24182742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure.
    Dubiner HB; Sircy MD; Landry T; Bergamini MV; Silver LH; Darell Turner F; Robertson S; Andrew RM; Weiner A; Przydryga J
    Clin Ther; 2004 Jan; 26(1):84-91. PubMed ID: 14996520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours.
    Liu JHK; Slight JR; Vittitow JL; Scassellati Sforzolini B; Weinreb RN
    Am J Ophthalmol; 2016 Sep; 169():249-257. PubMed ID: 27457257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure.
    Sit AJ; Weinreb RN; Crowston JG; Kripke DF; Liu JH
    Am J Ophthalmol; 2006 Jun; 141(6):1131-3. PubMed ID: 16765686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
    DuBiner HB; Hubatsch DA
    BMC Ophthalmol; 2014 Nov; 14():151. PubMed ID: 25432143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diurnal and nocturnal effects of travoprost in normal-tension glaucoma.
    Seibold LK; Kahook MY
    Clin Ophthalmol; 2014; 8():2189-93. PubMed ID: 25382969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
    Liu JH; Medeiros FA; Slight JR; Weinreb RN
    Ophthalmology; 2009 Mar; 116(3):449-54. PubMed ID: 19157559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of IOP reduction with travoprost BAK-free solution.
    Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
    J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
    Aihara M; Oshima H; Araie M;
    Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring.
    Cho SY; Kim YY; Yoo C; Lee TE
    Jpn J Ophthalmol; 2016 Jan; 60(1):27-34. PubMed ID: 26411460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.
    Lewis RA; Katz GJ; Weiss MJ; Landry TA; Dickerson JE; James JE; Hua SY; Sullivan EK; Montgomery DB; Wells DT; Bergamini MV;
    J Glaucoma; 2007 Jan; 16(1):98-103. PubMed ID: 17224758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between travoprost and central corneal thickness in ocular hypertension and open-angle glaucoma.
    Harasymowycz PJ; Papamatheakis DG; Ennis M; Brady M; Gordon KD;
    Cornea; 2007 Jan; 26(1):34-41. PubMed ID: 17198011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.
    Fellman RL; Sullivan EK; Ratliff M; Silver LH; Whitson JT; Turner FD; Weiner AL; Davis AA;
    Ophthalmology; 2002 May; 109(5):998-1008. PubMed ID: 11986110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
    Hughes BA; Bacharach J; Craven ER; Kaback MB; Mallick S; Landry TA; Bergamini MV
    J Glaucoma; 2005 Oct; 14(5):392-9. PubMed ID: 16148589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
    Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma.
    Gandolfi S; Paredes T; Goldberg I; Coote M; Wells A; Volksone L; Pillai MR; Stalmans I; Denis P;
    Eur J Ophthalmol; 2012; 22(1):34-44. PubMed ID: 22167541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.